Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HANSOH PHARMACEUTICAL (03692.HK) Innovative Drug XINYUE Receives Drug Registration Certificate for Third Indication
Recommend 1 Positive 0 Negative 0 |
||||
|
||||
|
HANSOH PHARMACEUTICAL (03692.HK) announced that its innovative drug XINYUE?(Inebilizumab Injection) has been granted a drug registration certificate by the National Medical Products Administration of China. The certificate approves an additional indication: the product is to be used in combination with conventional therapy for the treatment of adult patients with generalized myasthenia gravis who are positive for anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies. This marks the third approved indication for XINYUE. (de/d) Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
